Videos

In this discussion, Dr. Jeff Yu explores the topic of atopic dermatitis treatment news and the upcoming decision by the FDA on tapinarof for this skin disease.

In this Fall Clinical Dermatology Conference interview, Dr. Burgess answered several questions related to aesthetic treatments for patients with skin of color, including specific recommendations.

New PUNCH CD3 analyses show patients who were treated with live fecal microbiota therapy improved their gut health at 8 weeks—which correlated with improved quality-of-life scores.

Feuerstadt reviews ACG 2023 data showing live microbiota therapy provides consistent protection against rCDI in one of the most vulnerable patient populations.

No catch-all drug works to treat irritable bowel syndrome with constipation. But as the Mayo Clinic expert explains, enough unique options exist to tailor care better than ever.

In this interview, Dr. Yu explains several important pieces of information regarding atopic dermatitis that he believes clinicians should be aware of.

Study author Uma Mahadevan, MD, discusses her team's findings suggesting the concern of IBD flare risk in pregnant women receiving aspirin to prevent preeclampsia is unwarranted.

The study author discusses the clinical implications of his team's assessment into a risk factor score for alcohol relapse among post-transplant patients with ALD.

Investigator Brian E. Lacy, MD, PhD discusses new post hoc analysis that he hopes will provided clearer expectations for timing of benefit with tenapanor.

Dr. Song spoke in this segment of his interview on several more insightful elements from his presentation titled ‘Early Dermatology Practice Pearls.’

Investigator Jiten P. Kothadia, MD, discusses the advent of a predictive score for alcohol relapse risk in patients with alcohol liver disease who received a liver transplant in the last year.

In this interview segment, Dr. Song provided several unique viewpoints presented in his conference talk ‘Early Dermatology Practice Pearls.’

Thomas F. Imperiale, MD, discusses the pivotal findings showing improvements to the prior iteration of Cologuard, as well as bettered sensitivity and specificty relative to fecal immunochemical tests.

Data presented at ACG 2023 shows a significantly increased risk of infection and hospitalization due to RSV in patients with IBD. An investigator discusses implications during an era of increased vaccine options.

Dr. Eichenfield spoke in this interview segment on the tips shared in his presentation at the Fall Clinical Dermatology conference in Las Vegas.

In this interview, Dr. Eichenfield shared his views on this week’s approval by the FDA of IDP-126 for patients 12 and older with acne.

This interview segment explored the major takeaways from Dr. Chovatiya’s presentation on Type 2 Inflammation in eczema, prurigo nodularis, and chronic spontaneous urticaria.

In this interview segment, Dr. Chovatiya discussed the challenges of diagnosing Type 2 inflammation in several different dermatologic diseases.

In this interview, Dr. Chovatiya touched on several important updates and recent developments in the JAK inhibitor space for dermatologists.

In this interview segment, Dr. Nestor speaks on some of his biggest takeaways from his talk ‘What’s Coming Up Next?’ given at the Fall Clinical Dermatology conference.

This interview featured a discussion with Dr. Bhatia on the future of actinic keratosis diagnosis and treatment, as well as advances and important facts for clinicians to remember about risk.

Though rare, pediatric colon cancer often presents in advanced stages—emphasizing the need for awareness of risk factors and the opportunities borne from timely intervention.

Phase 2b data from the AHFIRM trial is anticipated soon. Reau discusses what the agent may show in treating alcohol-associated hepatitis.

This segment of Dr. Okoye’s interview featured a set of examples of HS patients’ struggles with access to medication, as well as discussion of potential solutions.

This interview with Dr. Okoye featured a discussion about her presentation at the SHSA conference, specifically regarding healthcare disparities for HS patients.

Shen explains how the pandemic affected the state of US elderly care, and discusses room for future research.

Shen discusses her team’s research into the link between high turnover rates in US nursing homes and worsened quality of care.

Ankeet Bhatt, MD, MBA provides additional perspective on a recent study examining the cost-effectiveness and health impact of sacubitril/valsartan use at different thresholds of ejection fraction.